Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Panetta Partners Limited
Road Town, British Virgin Islands
- Ownership
- Private
- Development stage
- Other
01
Overview
Panetta Partners Limited acts as an investment and intellectual property holding entity with a track record of originating and licensing drug development assets (e.g., chemerin-based peptides for treating ocular conditions, and small molecule assets for liver disease), commercializing via partnerships and assignments rather than direct clinical development[1][3].
- Therapeutic areas
- OphthalmologyGastroenterology
- Modalities
- Small moleculePeptideBiologic/Peptide-based therapies
- Industry
- Investors
02
Partnerships
OKYO Pharma (licensed Chemerin program)[1][4][8]Hepion Pharmaceuticals (acquired Rencofilstat asset)[3]On Target Therapeutics LLC (source of IP rights)[1]Tufts Medical Center (sublicense partner for IP)[1]
Beyond the preview
Go deeper on Panetta Partners Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panetta Partners Limited.